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Abstract
Purpose In this exploratory study, the effect of postprocedural flushing with crystalloids after oxaliplatin-based hyperthermic 
intraperitoneal chemotherapy (HIPEC) on platinum concentrations in peritoneal tissue, blood, and drain fluid was studied. 
Interpatient variability in oxaliplatin pharmacokinetics and the relation between platinum concentration in peritoneal fluid 
and platinum exposure in tissue and blood was explored.
Methods Ten patients with peritoneal carcinomatosis of colorectal origin were treated with HIPEC including postprocedural 
flushing, followed by ten patients without flushing afterwards. Tissue, peritoneal fluid, blood, and drain fluid samples were 
collected for measurement of total and ultrafiltered platinum concentrations.
Results Peritoneal tissue concentration and systemic ultrafiltered platinum exposure showed large inter individual vari-
ability, ranging from 65 to 1640 µg/g dry weight and 10.5 to 28.0 µg*h/ml, respectively. No effect of flushing was found on 
geometric mean platinum concentration in peritoneal tissue (348 vs. 356 µg/g dry weight), blood (14.8 vs. 18.1 µg*h/ml), or 
drain fluid (day 1: 7.6 vs. 7.7 µg/ml; day 2: 1.7 vs. 1.9 µg/ml). The platinum concentration in peritoneal fluid at the start of 
HIPEC differed twofold between patients and was positively correlated with systemic exposure (p = .04) and peak plasma 
concentration (p = .04).
Conclusion In this exploratory study, no effect was found for postprocedural flushing on platinum concentrations in perito-
neal tissue, blood, or drain fluid. BSA-based HIPEC procedure leads to large interpatient variability in platinum exposure 
in all compartments.
The study was registered at ClinicalTrials.gov on 7 December 2017 under registration number NCT03364907.
Keywords HIPEC · Hyperthermic intraperitoneal chemotherapy · Oxaliplatin · Peritoneal carcinomatosis · Colorectal 
peritoneal metastasis · Pharmacokinetics
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Introduction
Peritoneal metastasis of colorectal origin is identified 
in 5–10% of patients undergoing primary resection, and 
metachronous colorectal peritoneal metastasis occurs in 
20–50% of patients during follow-up [1–3]. Despite the 
use of modern systemic chemotherapy regimens, patients 
with peritoneal metastasis of colorectal cancer have poor 
outcome with a median overall survival of 10–16 months 
[4, 5]. Since the introduction of cytoreduction combined 
with hyperthermic intraperitoneal chemotherapy (HIPEC), 
median overall survival increased to 32–41 months [6–10].
The rationale for HIPEC is to obtain high local drug con-
centrations and high penetration in tumour tissue with rela-
tively low systemic exposure. The response of tumour cells 
is dependent on drug concentration in peritoneal fluid. In 
organoids derived from colorectal peritoneal metastases, a 
platinum concentration of 118–275 µg/ml in peritoneal fluid 
is required to eliminate 50% of tumour cells during 30-min 
HIPEC procedure [11]. Although these findings cannot be 
easily extrapolated to in vivo tumour nodules in patients, it 
provides insight in the importance of the drug concentration 
in peritoneal fluid. As diffusion is the most dominant mecha-
nism to penetrate in tissue for low-molecular-weight drugs, 
such as cisplatin and mitomycin C, higher drug concentra-
tion in peritoneal fluid results in higher drug concentration 
in tumour tissue [12]. Unfortunately, the optimal tissue con-
centration that is required to eliminate peritoneal metastases 
is unknown. It seems reasonable to strive for the highest 
local tissue concentration while limiting systemic exposure 
to prevent toxicity to the patient and the treating personnel 
in the postoperative period.[13, 14].
Although cytoreductive surgery (CRS) procedures are 
more or less standardised, large variations exist in HIPEC 
treatment modalities [15]. Important methodological varia-
tions include: technique (open ‘coliseum’ vs. closed abdo-
men), temperature, type and dose of the drug, exposure 
time, type and volume of carrier solution, and whether or 
not the peritoneum is flushed with crystalloids at the end of 
HIPEC. It is pivotal to understand the effects of these differ-
ent variations on pharmacokinetics and pharmacodynamics 
of the treatment. Postprocedural flushing is predominantly 
performed with the idea to minimise platinum concentra-
tion in blood and decrease platinum concentration in drain 
fluid after surgery, resulting in lower personnel exposure 
risk. On the other hand, it might decrease peritoneal tissue 
concentration and as such decrease efficacy of the treatment. 
If there is an effect of postprocedural flushing on platinum 
concentrations in tissue, blood, or drain fluid, this may affect 
efficacy and safety of the treatment.
The primary goal of this exploratory study was to eval-
uate the effect of flushing with NaCl 0.9% on platinum 
concentration in peritoneal tissue, blood, and drain fluid 
after oxaliplatin-based HIPEC. In addition, the interin-
dividual variability in tissue, blood, and drain fluid was 
explored and the relation between platinum concentra-
tion in peritoneal fluid at the start of HIPEC and platinum 
exposure in tissue and blood was investigated.
Materials and methods
Patients
Patients ≥ 18 years old with a diagnosis of preoperatively 
identified primary or recurrent peritoneal metastasis of colo-
rectal origin who were planned for HIPEC treatment with 
oxaliplatin according to routine clinical care were eligible 
for study entry. Patients were sequentially allocated over 
both groups, meaning that ten patients were enrolled in the 
flushing group, followed by ten patients in the non-flushing 
group.
The GUTOX trial was approved by the institutional ethics 
committee Arnhem-Nijmegen (Nijmegen) and was compli-
ant with the Declaration of Helsinki. All patients provided 
written informed consent before entering the study. The 
study was registered at ClinicalTrials.gov, NCT03364907.
Study design
The GUTOX study was an exploratory, single-center, pro-
spective, pharmacokinetic cohort study. The study design 
is graphically displayed in Fig. 1. In the flushing group, ten 
patients were treated with HIPEC including flushing after-
wards. Flushing consisted of rinsing the abdominal cavity 
with 0.9% (w/v) sodium chloride immediately after the intra-
peritoneal chemotherapy was drained out of the abdominal 
cavity. In the non-flushing group, ten patients underwent 
HIPEC without flushing afterwards. Surgical procedure 
was performed according to the local routine protocol for 
CRS-HIPEC procedure [16]. Oxaliplatin-based HIPEC was 
performed using the open coliseum technique at a dose of 
460 mg/m2, at a target temperature of 42–43 ℃ for a total 
duration of 30 min. Dextrose 5% was used as carrier solu-
tion. The volume of dextrose 5% was dependent on the 
abdominal volume which differed between patients. A flow 
rate of 1.2–2 L/min was used to circulate the perfusate. At 
the end of the chemoperfusion, the instillation solution was 
drained from the abdominal cavity.
Pharmacokinetic sampling and analytical assay
Pharmacokinetic sampling was performed as described 
in Fig. 1. At the end of HIPEC, a small peritoneal tissue 
sample (~ 1 × 2 cm) from the dorsal side of the posterior 
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rectus sheath was collected in patients of both groups. In 
the patients treated in the flushing group, a second perito-
neal sample was collected immediately after flushing with 
crystalloids. Peritoneal tissue pre-treatment was performed 
according to an earlier described method [14]. After HIPEC, 
four drainage tubes were fixed to drainage bags to collect 
outflowing drain fluid during the postoperative period as 
described in Fig. 1. The total volume of drain fluid per bag 
was noted, starting the morning after HIPEC. Immediately 
after sampling, the drain bags were changed. All samples 
were stored at − 40 ℃ until analysis. Platinum concentra-
tions were measured using flameless atomic absorption spec-
trometry according to a previously described method [17].
For non-compartmental pharmacokinetic analysis, Phoe-
nix WinNonlin® version 8.1 (Certara USA Inc, Princeton, 
NJ) was used.
Haematologic toxicity
The occurrence of haematologic toxicity was monitored for 
up to 14 days or until hospital discharge. Haematological 
lab monitoring took place as part of routine clinical care. 
Leukopenia, anaemia, and thrombocytopenia were graded 
according to Common Terminology Criteria for Adverse 
Events (CTCAE) v5.0 [18].
Fig. 1  Study design. CRS 
cytoreductive surgery, HIPEC 
hyperthermic intraperitoneal 
chemotherapy, PCI score 
Peritoneal Cancer Index score, 
CC score completeness of 
cytoreduction score. aHIPEC 
was performed with oxaliplatin 
460 mg/m2 at 42–43 °C for a 
duration of 30 min
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Statistics
Statistical analysis was performed using SPSS version 
25.0 (IBM Corp., Armonk, NY, USA). Pharmacokinetic 
parameters were described as geometric mean with range. 
Unpaired t tests were used to test for differences in patient 
characteristics with the exception of sex and CC score where 
a Chi-square test was performed. A paired sample t test was 
used on logarithmic transformed data to compare platinum 
tissue concentrations before and after postprocedural flush-
ing in the flushing group. Unpaired t tests were used on 
logarithmic transformed data to compare platinum tissue 
concentrations, systemic exposure, and platinum in drain 
fluid between both groups. A Fisher’s exact test was used to 
compare haematologic toxicity between both groups. Spear-
man’s rank correlation tests were used to test for correlations 
between platinum concentration in peritoneal fluid, tissue 
exposure, and unbound and total systemic exposure. p < 0.05 
were considered as statistically significant.
Results
Patients
Twenty patients were included in the GUTOX trial between 
March 2018 and June 2019. Patient characteristics are sum-
marised in Table 1. Despite a non-randomised study design, 
patient characteristics were equally distributed.
Peritoneal tissue
The interpatient variability in platinum concentrations in 
peritoneal tissue was substantial, ranging from 65–1640 µg/g 
dry weight. In the patients of the flushing group, no differ-
ence was found between the geometric mean [range] plati-
num concentrations in peritoneal tissue before and after 
postprocedural flushing (348 [66–1571] µg/g dry weight vs. 
356 [65–1025] µg/g dry weight, respectively; p = 0.927). 
The platinum tissue concentrations pre- and post-flushing 
are graphically displayed in Fig. 2. The non-flushing group 
showed similar geometric mean [range] platinum concen-
trations in peritoneal tissue compared to the flushing group 
before postprocedural flushing (478 [202–1640] µg/g dry 
weight vs. 348 [66–1571] µg/g dry weight, respectively; 
p = 0.416).
Blood
Interpatient variability in systemic exposure of ultra-
filtered platinum and total platinum was 30% and 25%, 
respectively. Systemic exposure for ultrafiltered platinum 
and total platinum ranged from 10.5 to 28.0 µg*h/ml and 
62.3 to 168.4 µg*h/ml, respectively. The patients of the 
flushing group showed lower geometric mean [range]  Cmax 
for both ultrafiltered platinum and total platinum than the 
patients of the non-flushing group  (Cmax total platinum: 
6.3 [5.0–8.6] µg/ml vs. 8.0 [5.5–11.6] µg/ml, respectively; 
p = 0.024 and  Cmax ultrafiltered platinum: 4.6 [3.5–5.7] µg/
ml vs. 5.9 [3.4–8.7] µg/ml, respectively; p = 0.043). Geo-
metric mean [range] systemic exposure of total platinum 
was lower in the flushing group compared to the non-
flushing group (90.4 [62.3–105.8]  µg*h/ml vs. 116.4 
[79.5–168.4] µg*h/ml, respectively; p = 0.019). There was 
no difference in geometric mean [range] systemic expo-
sure of ultrafiltered platinum between both groups (14.8 
[10.5–20.2] µg*h/ml vs. 18.1 [10.8–28.0] µg*h/ml, respec-
tively; p = 0.141). Platinum pharmacokinetics of unbound 
Table 1  Patients’ characteristics
Data are presented as mean ± SD or as median (IQR)
PCI score Peritoneal Cancer Index score, CC score completeness of cytoreduction score, eGFR estimated 
glomerular filtration rate, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration
Flushing
(n = 10)
Non-flushing (n = 10) p value
Age (year) 65 ± 15 63 ± 11 0.815
Sex (M/F) 6/4 3/7 0.178
Body mass index (kg/m2) 26.6 ± 3.8 28.4 ± 4.8 0.356
Body surface area  (m2) 1.90 (1.76–2.10) 1.97 (1.80–2.12) 0.590
PCI score 4 (2–13) 8 (5–13) 0.423
CC score
 CC-0 10 9 0.305
 CC-1 0 1
Karnofsky score 90 (90–90) 90 (90–90) 1.000
Peritoneal metastasis (primary/recurrent) 10/0 10/0 1.000
eGFR using CKD-EPI (ml/min/1.73m2) 87 ± 5 88 ± 4 0.559
145Cancer Chemotherapy and Pharmacology (2020) 86:141–150 
1 3
and total platinum in plasma during HIPEC and the first 
4 h post-HIPEC are shown in Fig. 3.
Drain fluid
The geometric mean [range] of platinum cleared via 
drainage during the first 2 days after HIPEC did not 
differ between both groups (4.5 [2.6–7.7]  mg vs. 6.3 
[3.0–11.8] mg, respectively; p = 0.054). No differences 
were found between both groups in geometric mean 
[range] platinum concentration in drain fluid on day 1 
post-HIPEC (7.6 [2.8–21.1] µg/ml vs. 7.7 [3.8–14.6] µg/
ml, respectively; p = 0.953) or day 2 post-HIPEC (1.7 
[0.7–5.4]  µg/ml vs. 1.9 [1.4–3.1]  µg/ml, respectively; 
p = 0.523). The platinum cleared via drainage appeared to 
be only a minor part (approximately 0.6%) of the totally 
administered dose.
Peritoneal fluid
Platinum concentration at start of HIPEC showed substan-
tial interpatient variability, ranging from 122—246 µg/ml. 
On average, the total volume of peritoneal fluid, platinum 
concentration at start, and total exposure over 0–30 min in 
peritoneal fluid did not differ between the two groups. The 
peritoneal fluid concentration–time curve during HIPEC is 
shown in Fig. 4. All the platinum in peritoneal fluid was 
unbound platinum. During the 30-min oxaliplatin perfusion, 
total platinum concentration in peritoneal fluid decreased 
from 180 (± 39) µg/ml to 129 (± 26) µg/ml in the flushing 
group and from 191 (± 24) µg/ml to 133 (± 23) µg/ml in 
the non-flushing group, reflecting a decrease of approxi-
mately 28% and 30%, respectively. Postprocedural flushing 
decreased platinum concentration to negligible concentra-
tions of 8 µg/ml, which is ~ 4% of the concentration at start.
Correlations
Spearman’s correlation tests showed that ultrafiltered plati-
num concentration in peritoneal fluid at the start of HIPEC 
was positively correlated with both total systemic exposure 
(p = 0.04) and peak plasma concentration (p = 0.04), and 
negatively correlated with perfusate volume (p =  < 0.01). 
The peak ultrafiltered platinum plasma concentration was 
negatively correlated with perfusate volume (p = 0.04). No 
correlations were found between platinum concentration in 
peritoneal fluid at the start of HIPEC and tissue exposure.
Pharmacologic parameters are summarised in Table 2. 
Correlations between the described variables are shown in 
a scatterplot in Fig. 5.
Haematologic toxicity
No difference was found in haematological toxicity 
between both groups (Table  3). None of the patients 
Fig. 2  Platinum exposure in 
peritoneal tissue. a Boxplots 
of platinum peritoneal tissue 
concentration in patients of the 
flushing and the non-flushing 
group. b Individual platinum 
peritoneal tissue concentrations 
showing individual differences 
between pre- and post-flushing. 
Peritoneal tissue concentrations 
of patients of the non-flushing 
group are presented together 
with the pre-flushing tissue 
concentrations. Pt platinum
Fig. 3  Plasma concentration–time curve during first 4 h including the 
30 min of HIPEC. Data are presented as mean ± SD, Pt platinum, UF 
Pt ultrafiltered platinum
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Fig. 4  Peritoneal fluid con-
centration–time curve during 
HIPEC. The start concentration 
at timepoint 0 is a theoretical 
concentration calculated using 
the administered dose and the 
total peritoneal fluid admin-
istered. Data are presented as 
mean ± SD, Pt Platinum, UF Pt 
ultrafiltered platinum
Table 2  Pharmacologic parameters
Data are presented as mean ± SD or as geometric mean [range]
Pt Platinum, AUC 0-0,5 h Area under the concentration–time curve from 0 to 0,5 h, Cmax peak plasma concentration, AUC 0-72 h Area under the 
concentration–time curve from 0 to 72 h, AUC 0-inf Area under the concentration–time curve from 0 to infinite time, UF Pt ultrafiltered platinum
P values < 0.05 are considered statistically significant and are flagged with one asterisk (*)
a based on paired t test
Flushing (n = 10) Non-flushing (n = 10) p value
General information
 Oxaliplatin dose (mg) 877 ± 83 902 ± 124 0.603
 Intravenous fluid administered between 1 h prior to HIPEC until 
the end of HIPEC (ml)
1193 ± 568 1114 ± 592 0.764
Peritoneal tissue
 Pt concentration in tissue pre-flushing (µg/g dry weight) 348 [66–1571] 478 [202–1640] 0.416
 Pt concentration in tissue post-flushing (µg/g dry weight) 356 [65–1025] – 0.927a
Plasma
 Cmax total Pt (µg/ml) 6.3 [5.0–8.6] 8.0 [ 5.5–11.6] 0.024*
 AUC 0-72 h total Pt (µg*h/ml) 90.4 [62.3–105.8] 116.4 [79.5–168.4] 0.019*
 AUC 0-inf total Pt (µg*h/ml) 137.2 [77.2–209.2] 169.8 [117.6–285.2] 0.110
 Cmax UF Pt (µg/ml) 4.6 [3.5–5.7] 5.9 [3.4–8.7] 0.043*
 AUC 0-72 h UF Pt (µg*h/ml) 14.8 [10.5–20.2] 18.1 [10.8–28.0] 0.141
 AUC 0-inf UF Pt (µg*h/ml) 15.5 [11.1–21.9] 18.8 [11.2–29.0] 0.151
Drain fluid
 Volume produced during first 2 days (ml) 1142 [460–2280] 1312 [650–3025] 0.524
 Pt cleared during first 2 days after HIPEC (mg) 4.5 [2.6–7.7] 6.3 [3.0–11.8] 0.054
 Pt concentration on day 1 after HIPEC (µg/ml) 7.6 [2.8–21.1] 7.7 [3.8–14.6] 0.953
 Pt concentration on day 2 after HIPEC (µg/ml) 1.7 [0.7–5.4] 1.9 [1.4–3.1] 0.523
Peritoneal fluid
 Volume of perfusate (ml) 5077 ± 1163 4755 ± 756 0.474
 Pt concentration at the start of HIPEC (µg/ml) 180 ± 39 191 ± 24 0.450
 Pt concentration at the end of HIPEC (µg/ml) 129 ± 26 133 ± 23 0.734
 Pt concentration after flushing (µg/ml) 8 ± 8 – –
 AUC 0-0.5 h peritoneal fluid (µg*h/ml) 73.1 [48.6–109.6] 75.9 [63.7–100.4] 0.664
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developed leukopenia. Any grade anaemia occurred in 
90% of all patients (100% of the patients in the flushing 
group vs. 80% in the non-flushing group). Four patients 
in the flushing group and one patient in the non-flushing 
group experienced grade 3 anaemia. The median [range] 
time to nadir anaemia appeared 5 [1–10] days post-HIPEC 
in the flushing group and 3 [1–12] days post-HIPEC 
in the non-flushing group. Grade 1 thrombocytopenia 
occurred in 30% of the patients in both treatment groups. 
Median [range] time to nadir thrombocytes was 2 [1–4] 
days post-HIPEC.
Discussion
Substantial interpatient variability was demonstrated for 
platinum concentrations in both peritoneal tissue, blood, and 
drain fluid during and after HIPEC procedure. Assuming that 
platinum exposure correlates with efficacy and safety of the 
treatment, the observed interpatient pharmacokinetic varia-
bility might affect treatment outcome and should be reduced. 
It is important to know which variations in HIPEC proce-
dure contribute to high variability in platinum exposure. 
The GUTOX study evaluates the effect of postprocedural 
flushing on pharmacokinetics of oxaliplatin. In this explora-
tory study, no significant effect of flushing after HIPEC on 
platinum concentration in peritoneal tissue, blood, or drain 
fluid was detected, although a yet unexplained difference in 
systemic exposure between patients who were and were not 
flushed after the HIPEC procedure was observed.
Since platinum concentrations were prospectively col-
lected in multiple compartments, including peritoneal fluid, 
peritoneal tissue, blood, and drain fluid, and this study 
provides insights in the further understanding of oxalipl-
atin distribution during HIPEC procedure. High platinum 
concentration in microscopic remnants of tumour after 
cytoreduction is important for efficacy of HIPEC [11, 19]. 
Platinum tissue concentrations in healthy peritoneal tissue 
instead of tumour tissue were measured, because tumour 
nodules need to be resected prior to HIPEC to give the 
patient probably most benefit from the procedure. This is a 
feasible approach, since Elias et al. showed in earlier studies 
Fig. 5  Statistical significant 
correlations. Scatterplots with 
Spearman’s correlation coef-
ficient (R) and Sig(2-tailed) 
p value (p). Pt concentration 
in peritoneal fluid at start of 
HIPEC is positively correlated 
with both AUC 0-72 h Pt UF (a) 
and  Cmax UF Pt (b) in plasma 
and negatively correlated with 
perfusate volume (c).  Cmax UF 
Pt in plasma is negatively corre-
lated with perfusate volume (d). 
Pt Platinum, UF Pt ultrafiltered 
platinum, AUC 0-72 h Area under 
the curve from 0 to 72 h, Cmax 
peak plasma concentration







 Any 0 0 1.000
 Severe (grade 3 and 4) 0 0 1.000
Anaemia
 Any 10 8 0.474
 Severe (grade 3 and 4) 4 1 0.303
Thrombocytopenia
 Any 3 3 1.000
 Severe (grade 3 and 4) 0 0 1.000
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that platinum tissue concentration after HIPEC is similar 
between tumour and healthy peritoneal tissue [14].
The analytical method used to quantify platinum in this 
study was not validated for measurement of platinum in 
peritoneal tissue and drain fluid. Nevertheless, it is unlikely 
that matrix will influence the analysis using the technique of 
atomic absorption spectrometry, since, with this technique, 
the total sample is burned at high temperature to vaporise 
and atomise elements including platinum that is being ana-
lysed. Patients were not randomised over both treatment 
groups, but were sequentially allocated to the flushing- and 
non-flushing groups. The local HIPEC protocol that was 
used for routine clinical care at the beginning of the study 
included postprocedural flushing. After the inclusion of the 
first ten patients in this study, the local HIPEC protocol was 
changed to HIPEC without postprocedural flushing. This 
indicates that all HIPEC patients, regardless of whether they 
participated in this study, were treated conform the prevail-
ing local HIPEC protocol. Although no randomisation was 
performed, the patient characteristics were well balanced 
between both treatment groups. Additionally, no stratifica-
tion was performed for factors that may influence platinum 
concentration in tissue, e.g., volume of perfusate and perito-
neal fluid concentration, since these factors cannot be deter-
mined before the procedure.
Interpatient variability in platinum concentration in dried 
peritoneal tissue was high, which is in line with earlier find-
ings [12]. The median tissue concentrations found in this 
study match with the results of Elias et al. who found a 
peritoneal platinum tissue exposure of 392 µg/g dry weight, 
using a similar HIPEC method [14]. HIPEC performed with 
a lower dose of 300 mg/m2 resulted in a notable lower peri-
toneal tissue concentration of only 50 µg/g dry weight [range 
5–203 µg/g dry weight] [20]. In the GUTOX study, a cor-
relation between platinum concentration in peritoneal fluid 
and peritoneal tissue could not be demonstrated. However, 
others demonstrated that higher platinum concentrations 
in peritoneal fluid resulted in higher tissue exposure [12]. 
Oxaliplatin was dosed based on BSA which resulted in a 
large range of platinum concentrations in peritoneal fluid of 
122–246 µg/ml. From a pharmacological point of view, the 
use of a fixed drug concentration should be preferred when 
performing HIPEC. Concentration-based HIPEC should be 
incorporated in global standardisation of HIPEC protocols, 
which is unfortunately still not the case. Nevertheless, even 
when HIPEC is performed with a fixed oxaliplatin concen-
tration, the interpatient variety is still high [12]. This sug-
gests that in addition to peritoneal platinum concentrations, 
other factors will influence tissue exposure and thereby effi-
cacy of the treatment.
The peak plasma concentration of total and ultrafiltered 
platinum was reached at the end of HIPEC and rapidly 
dropped after removing oxaliplatin from the abdominal 
cavity. The higher peak concentration and exposure over 
time for platinum in the non-flushing group was caused by 
a difference in absorption of platinum in the first 30 min of 
HIPEC, as can be seen in Fig. 3. The observed difference 
cannot be explained by an effect of flushing, because the pro-
cedure for both groups did not differ during the first 30 min 
of the HIPEC procedure. The observed difference could nei-
ther be explained by differences in renal function, platinum 
concentration in peritoneal fluid, absolute dose, extent of 
surgery, nor the amount of intravenous fluid administered 
around HIPEC procedure. Therefore, the observed difference 
is yet unexplained and needs further attention.
Interpatient variability in systemic exposure is considered 
moderate and is comparable with between-patient variability 
of 33% after intravenous administration [21], while others 
report lower interpatient variability for total platinum and 
ultrafiltered platinum of 12% and 4–15%, respectively [22]. 
The unbound platinum concentration is generally considered 
as the pharmacologically active moiety [21, 23]. The peak 
plasma concentration of ultrafiltered platinum observed in 
the GUTOX study (flushing: 4.6 and non-flushing: 5.9 µg/
ml) after intraperitoneal administration of oxaliplatin in a 
dose of 460 mg/m2 was higher than the peak plasma con-
centration of ultrafiltered platinum observed after a 2-h 
intravenous infusion of oxaliplatin at a dose of 130 mg/m2 
(1.21 µg/ml) [21]. This suggests a faster systemic absorption, 
which seems pharmacological plausible when administering 
a higher dose over a shorter time period. More important, the 
average total exposure over time for ultrafiltered platinum 
observed in the GUTOX study (15.5 and 18.8 µg*h/ml) is 
higher than the total systemic exposure for ultrafiltered plati-
num after a single 2-h infusion of oxaliplatin at 130 mg/m2 
(11.9 µg*h/ml) [21]. Nevertheless, no oxaliplatin induced 
haematologic toxicity was identified in this study. Anaemia 
is a very common complication in the immediate postop-
erative period being present in up to 90% of patients after 
major surgery [24]. Usually, leukocytes and platelets reach 
their nadir within 7–14 days after chemotherapy. Erythro-
cytes live for approximately 120 days [25] and, therefore, 
will not reach a nadir for several weeks after treatment. In 
this study, nadir anaemia was observed after a median time 
of 3–5 days post-HIPEC. Therefore, the anaemia observed in 
this study should be contributed to the operative procedure 
and is unlikely related to oxaliplatin.
The most important contamination sources during post-
operative care of the patients is the personnel exposure to 
urine and drain fluid from an HIPEC-patient. The concen-
tration in drain fluid on day 2 was about five times lower 
compared to day 1. The platinum concentration in drain 
fluid on both days did not differ between the groups. How-
ever, a trend towards a difference in the absolute amount 
of platinum cleared via drain fluid was found. This can be 
explained by a higher total volume of produced drain fluid 
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in the non- flushing group. The risk for personnel exposure 
is considered to be related with the platinum concentration 
and not with the absolute amount in drain fluid [26]. These 
results are in line with earlier findings reporting ranges in 
platinum concentrations in drain fluid of 0.6–13.2 µg/ml 
on day 1 post-HIPEC and 0.2–3.2 µg/ml on day 2 post-
HIPEC [27]. These data underline the importance of safety 
precautions when handling drain fluid of HIPEC patients. 
Postprocedural flushing after HIPEC does not seem to 
reduce the risk for personnel exposure.
On average, no difference was found between total vol-
ume of perfusate and platinum concentration in peritoneal 
fluid at start of HIPEC between both groups. Although it 
is important to notice that the platinum concentration in 
peritoneal fluid differed up to twofold between individual 
patients (122 vs. 246 µg/ml), which might affect antitu-
mour activity at the peritoneal level. The decline of free 
platinum in peritoneal fluid is mainly the result of absorp-
tion from the peritoneal compartment towards peritoneal 
tissue and the systemic compartment. Reactions with 
erythrocytes and other cell types or debris in perfusate are 
unlikely to occur. All platinum in peritoneal fluid consisted 
of free unbound platinum. A decrease of approximately 
30% in total platinum concentration in peritoneal fluid 
was found which is consistent with the literature report-
ing decreases of 30–50% [12, 28].
In this exploratory study, no effect was found for post-
procedural flushing after oxaliplatin-based HIPEC on plat-
inum concentrations in peritoneal tissue, blood, or drain 
fluid. A detrimental effect of flushing on efficacy or safety 
of the treatment seems unlikely and, therefore, the use 
of postprocedural flushing should be debated to simplify 
the HIPEC procedure. This study showed that BSA-based 
HIPEC procedure leads to large interpatient variability in 
platinum exposure in all compartments. Assuming that 
exposure correlates with treatment outcome, the observed 
sources of variability in platinum exposure need to be fur-
ther investigated.
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